FMP

FMP

Enter

ALPN - Alpine Immune Scienc...

Financial Summary of Alpine Immune Sciences, Inc.(ALPN), Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery a

photo-url-https://financialmodelingprep.com/image-stock/ALPN.png

Alpine Immune Sciences, Inc.

ALPN

NASDAQ

Inactive Equity

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

64.97 USD

0.01 (0.01539%)

About

ceo

Dr. Mitchell H. Gold M.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with Ab...

CIK

0001626199

ISIN

US02083G1004

CUSIP

02083G100

Address

188 East Blaine Street

Phone

206 788 4545

Country

US

Employee

142

IPO Date

Jun 17, 2015

Summary

CIK

0001626199

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

02083G100

ISIN

US02083G1004

Country

US

Price

64.97

Beta

0.97

Volume Avg.

2.37M

Market Cap

4.46B

Shares

-

52-Week

8.33-65.0

DCF

-0.15

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-101.52

P/B

-

Website

https://www.alpineimmunesciences.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest ALPN News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep